Wallingford, Connecticut 06492

  • Chickenpox


To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with varicella-zoster viral disease who have failed or are intolerant of alternative therapy.

Study summary:

Any physician qualified to treat pediatric AIDS patients may enroll patients in this study.


Inclusion Criteria Patients must have: - HIV infection. - Cutaneous, visceral, or ocular varicella-zoster viral infection. - Refractory or intolerant to acyclovir or foscarnet therapy. - Consent of parent or guardian. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Inability to take oral capsules or tolerate liquids. Concurrent Medication: Excluded: - 5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid. Patients with the following prior condition are excluded: History of immediate hypersensitivity to nucleoside analogues. Prior Medication: Excluded: - 5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid within 4 weeks prior to study entry. Required: - Prior acyclovir or foscarnet.



Primary Contact:


Backup Contact:


Location Contact:

Wallingford, Connecticut 06492
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: June 20, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.